---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-265755"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2022-10-20T23:59:59+00:00"
generated_at: "2026-06-23T02:26:00.425074+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amgen completes $3.7B acquisition of ChemoCentryx, adding TAVNEOS to portfolio

## Summary
- Acquisition closed at $52 per share in cash, aggregate consideration ~$3.7 billion.
- Adds TAVNEOS (avacopan), a first-in-class oral therapy for severe active ANCA-associated vasculitis.
- Also includes three early-stage drug candidates targeting chemoattractant receptors and an oral checkpoint for cancer.
- TAVNEOS approved by FDA in Oct 2021; being studied in hidradenitis suppurativa and C3 glomerulopathy.

## SEC filing metadata
- accession: 0001193125-22-265755
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2022-10-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000119312522265755/0001193125-22-265755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000119312522265755/d414605d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-265755
- JSON: https://secwatch.observer/filing/0001193125-22-265755.json
- Plain text: https://secwatch.observer/filing/0001193125-22-265755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.